Ledesma G, Umpierrez GE, Morley JE, et al. - In older patients with T2DM on stable insulin therapy, researchers conducted this phase 4, randomized, multicenter, double-blinded, placebo-controlled, 24-week study to evaluate the addition of linagliptin as an alternative to insulin up-titration. The study sample consisted of people on stable insulin, with baseline HbA1c 7.0–10.0%, age ≥ 60 years, and BMI ≤ 45 kg/m². For this investigation, 302 candidates were randomized 1:1 to linagliptin 5 mg QD and placebo, with one-third of patients from Japan. In older T2DM patients with stable insulin therapy, the addition of linagliptin improves glucose control without excess hypoglycemia.